BioWorld

Jan. 21, 2003

View Archived Issues

Amgen Hits Endpoints In First Enbrel Psoriasis Phase III Trial

The first of two Enbrel Phase III trials in psoriasis hit its primary and secondary endpoints, pushing Amgen Inc. to the halfway point in its quest to grow the blockbuster drug through the addition of another large market. (BioWorld Today) Read More

NPS's Phase III Bone Treatment Tested In Shuttle's Microgravity

Read More

FDA's Authority Over Cloning Questioned At Council Meeting

Read More

Holiday Notice

BioWorld's offices were closed Monday in observance of the Martin Luther King Jr. holiday in the U.S. No issue was published that day. Read More

Amylin Sells 9.2M Shares, Raises $152.7M For Symlin

Read More

Other News To Note

Read More

Appointments And Advancements

Read More